13233
clinical study

Unveiling the Impact of Riverain's Vessel Suppression: Breakthrough or Bust?

Materials & Methods

This retrospective study evaluates the impact of vessel suppression on radiology residents’ reading speed and detection of ≤2mm pulmonary nodules over 14 months, before and after implementation. It includes CT chest exams for patients with malignancy risk. Reading times were measured, and final reports were analyzed using natural language processing (NLP) algorithms to assess nodule size and detection rates.

Results

A total of 4,429 CT chest scans were analyzed (1,002 pre- and 3,427 post-implementation). After vessel suppression implementation, average reading time significantly decreased from 19.1 to 12.2 minutes (p<0.01), and punctate pulmonary nodule detection increased from 13.0% to 24.2% (p<0.01).

Conclusions

Vessel suppression can enhance CT chest reading speed for radiology residents, particularly in high-risk cancer patients, while also increasing punctate nodule detection. 

Disclaimer: This links to a third-party website, which may require credentials to review. 

Explore the Latest AI Insights, Trends and Research

Deepak Srikant

<p>Deepak Srikant is a global marketing executive with over 20 years of experience, specializing in the commercialization of medical devices and digital health solutions. He has a proven track record in driving growth, having led successful go-to-market strategies, product launches and market expansions across the U.S. and EMEA.</p> <p>Srikant’s expertise extends to upstream and downstream marketing, professional education and sales enablement. His leadership at companies such as Silk Road Medical (acquired by Boston Scientific) and Aptus Endosystems (acquired by Medtronic) has consistently resulted in revenue growth, enhanced customer retention and successful product adoption.</p> <p>Srikant holds an MBA from the Yale School of Management and a bachelor’s degree in mechanical engineering from Rensselaer Polytechnic Institute. Currently, he leads product marketing for Aidoc’s cardiovascular service line.</p>

Laci Costa

<p>Laci Costa is the Director of Neurovascular Product Marketing at Aidoc. She leads marketing and commercial strategy for the neuro AI portfolio of products. She has 16 years of experience working in the medical device and healthcare industry, with over 12 years dedicated to neurovascular solutions.</p> <p>Costa’s known for her expertise in the neurovascular industry, go-to-market experience with new technologies and upstream and downstream product marketing leadership. She’s held various leadership positions in product marketing, clinical education and professional affairs spanning across start-up organizations to large publicly traded companies.</p> <p>Costa holds a bachelor’s degree in psychology from the University of Oklahoma and an MBA from USC Marshall School of Business.</p>

Ayden Jacob, MD, MSc

<p>Ayden Jacob, MD, MSc, is a physician-engineer with expertise in AI, data science and healthcare economics. He’s passionate about leveraging AI and data science to solve complex healthcare issues through the specific prism of economics and finance. At Aidoc, Dr. Jacob’s work focuses on quantifying the clinical and financial impact of innovative AI solutions deployed throughout the healthcare ecosystem.</p> <p>Dr. Jacob’s diverse expertise reflects a commitment to advancing healthcare through data-driven solutions that enhance both patient outcomes and operational effectiveness. A graduate of Yeshiva University and the University of Oxford, Dr. Jacob employs an interdisciplinary approach to innovating at the intersection of clinical medicine, engineering and informatics.</p>